4-Chlorobenzenesulfonamide | CAS#98-64-6 | sulfonamide derivative

MedKoo Cat#: 591645 | Name: 4-Chlorobenzenesulfonamide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

4-Chlorobenzenesulfonamide is a sulfonamide derivative.

Chemical Structure

4-Chlorobenzenesulfonamide

CAS#98-64-6

Theoretical Analysis

MedKoo Cat#: 591645

Name: 4-Chlorobenzenesulfonamide

CAS#: 98-64-6

Chemical Formula: C6H6ClNO2S

Exact Mass: 190.9808

Molecular Weight: 191.63

Elemental Analysis: C, 37.61; H, 3.16; Cl, 18.50; N, 7.31; O, 16.70; S, 16.73

Price and Availability

Size	Price	Availability
5g	USD 250.00	2 Weeks
10g	USD 350.00	2 Weeks
25g	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

4-Chlorobenzenesulfonamide; NSC 403674; NSC-403674; NSC403674

IUPAC/Chemical Name

4-Chlorobenzenesulphonamide

InChi Key

HHHDJHHNEURCNV-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H6ClNO2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,(H2,8,9,10)

SMILES Code

O=S(C1=CC=C(Cl)C=C1)(N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 191.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rehman A, Abbasi MA, Siddiqui SZ, Mohyuddin A, Nadeem S, Shah SA. Synthesis, spectral analysis and biological evaluation of Nalkyl/aralkyl/aryl-4-chlorobenzenesulfonamide derivatives. Pak J Pharm Sci. 2016 Sep;29(5):1489-1496. PubMed PMID: 27731801. 2: Wang L, Mori W, Cheng R, Yui J, Hatori A, Ma L, Zhang Y, Rotstein BH, Fujinaga M, Shimoda Y, Yamasaki T, Xie L, Nagai Y, Minamimoto T, Higuchi M, Vasdev N, Zhang MR, Liang SH. Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase. Theranostics. 2016 May 21;6(8):1145-59. doi: 10.7150/thno.15257. eCollection 2016. PubMed PMID: 27279908; PubMed Central PMCID: PMC4893642. 3: Kim KY, Cho HS, Lee SH, Ahn JH, Cheon HG. Neuroprotective effects of KR-62980, a new PPARγ agonist, against chemical ischemia-reperfusion in SK-N-SH cells. Brain Res. 2011 Feb 4;1372:103-14. doi: 10.1016/j.brainres.2010.11.062. Epub 2010 Nov 25. PubMed PMID: 21111719. 4: Varnes JG, Forst JM, Hoerter TN, Holmquist CR, Wilkins DE, Tian G, Jonak G, Wang X, Potts WM, Wood MW, Alhambra C, Brugel TA, Albert JS. Identification of N-(2-(azepan-1-yl)-2-phenylethyl)-benzenesulfonamides as novel inhibitors of GlyT1. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4878-81. doi: 10.1016/j.bmcl.2010.06.085. Epub 2010 Jun 19. PubMed PMID: 20637614. 5: Sławiński J, Brzozowski Z. Synthesis and in vitro antitumor activity of novel series 2-benzylthio-4-chlorobenzenesulfonamide derivatives. Eur J Med Chem. 2006 Oct;41(10):1180-9. Epub 2006 Jun 14. PubMed PMID: 16777268. 6: Tang FL, Yuan G, Wang J. Synthesis and photoinduced DNA cleaving activity of hairpin polyamide-chlorobenzenesulfonyl conjugates. Photochem Photobiol. 2003 Aug;78(2):175-9. PubMed PMID: 12945586. 7: Schroeder PE, Davidson JN, Hasinoff BB. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos. 2002 Dec;30(12):1431-5. PubMed PMID: 12433815. 8: Hoogenboom LA, van Bruchem GD, Sonne K, Enninga IC, van Rhijn JA, Heskamp H, Huveneers-Oorsprong MB, van der Hoeven JC, Kuiper HA. Absorption of a mutagenic metabolite released from protein-bound residues of furazolidone. Environ Toxicol Pharmacol. 2002 Jul;11(3-4):273-87. PubMed PMID: 21782611. 9: Hasinoff BB, Reinders FX, Clark V. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Dispos. 1991 Jan-Feb;19(1):74-80. PubMed PMID: 1673425. 10: Clark CR, McMillian CL. Comparative anticonvulsant activity of 4-chlorobenzenesulfonamide and prototype antiepileptic drugs in rodents. Epilepsia. 1990 Jul-Aug;31(4):474-9. PubMed PMID: 2114972. 11: Ventre ER. Determination of the content of 2-chlorobenzenesulphonamide and bis(p-chlorophenyl) sulphone in 4-chlorobenzenesulphonamide. J Chromatogr. 1985 Sep 27;333(1):253-5. PubMed PMID: 4066841.